Study of the Prevalence of Iron Deficiency in Elderly Patient in Hospital Environment (CARENFERPA)

Iron deficiency is defined by insufficient tissue iron stores and anemia is the ultimate stage of iron deficiency. Anemia should never be neglected in an elderly subject because it is associated with an increase in mortality, but also with a increased morbidity in terms of complications

Apart from anemia, iron deficiency is common and constitutes a factor of poor prognosis in diseases chronic, all pathologies very frequently found in the elderly. It is the origin of the deterioration in the general condition of patients, their re-hospitalization or even the progression of their pathology.

In this context where elderly patients also present a certain number of comorbidities including the pathologies mentioned previously, it is important to better diagnose the deficiency martial in the elderly patient.

Study Overview

• Status: Completed
• Conditions: Iron-deficiency
• Intervention / Treatment: Diagnostic test: Blood sampling

Detailed Description

Iron deficiency (MD) is defined by insufficient tissue iron stores. Since iron is essential for the synthesis of hemoglobin, when the iron deficiency no longer makes it possible to maintain a sufficient level of erythropoiesis, anemia appears: it is the ultimate stage of iron deficiency.

Anemia is the most common haematological pathology encountered in geriatric practice. Its prevalence, in population generally ambulatory, is between 10 and 15% after the age of 65 and is greater than 20% beyond the age of 85.

Anemia should never be neglected in an elderly subject because it is associated with an increase in mortality, but also with a increased morbidity in terms of complications heart disease, cognitive decline, frailty, hospitalizations, and impairment of quality of life. About a third of anemias elderly person is attributable to a deficiency in vitamin B9 or B12 or an iron deficiency.

Apart from anemia, iron deficiency is common and constitutes a factor of poor prognosis in diseases chronic such as heart failure, kidney failure chronic or cancer, all pathologies very frequently found in the elderly. It is the origin of the deterioration in the general condition of patients, their re-hospitalization or even the progression of their pathology.

In this context where elderly patients also present a certain number of comorbidities including the pathologies mentioned previously, it is important to better diagnose the deficiency martial in the elderly patient.

This diagnosis is all the more important because, depending on the chronic pathology, data from the literature have shown that correcting the iron deficiency brings benefits to the patient by reducing the risk of recurrence of anemia, the prescription of erythropoietin and the use of transfusion for patients in oncology, gastroenterology and nephrology

• Study Type: Interventional
• Enrollment (Actual): 888
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • ANGERS Cedex 9, France, 49933
    • CHU Angers
  • Bayonne, France, 64100
    • CH de Bayonne
  • Calais Cedex, France, 62107
    • CH de Calais
  • Chambéry, France, 73000
    • CH Chambery
  • Corbeil-Essonnes, France, 91100
    • CHSF
  • Dunkerque Cedex 1, France, 59385
    • CH de Dunkerque
  • Lille Cedex, France, 59037
    • Hôpital Gériatrique Les Bateliers Chu Lille
  • Nantes Cedex 1, France, France
    • Chu De Nantes, Hôpital Bellier
  • Nice, France, 6003
    • CHU de NICE-hopital CIMIEZ
  • Paris Cedex 12, France, 75571
    • Hopital Saint Antoine
  • Pau, France, 64000
    • CH de Pau
  • Poitiers, France, 86021
    • CHU De Poitiers
  • Strasbourg, France, 67000
    • HUS - Hôpitaux Universitaires de Starsbourg
  • Tours Cedex 9, France, 37044
    • Hopital Bretonneau
  • Vandoeuvre-Lès-Nancy, France, 54511
    • CHU Nancy
  • Villeurbanne, France, 69100
    • HCL

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 75 years and older (Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Any patient hospitalized in a geriatric unit (short geriatric stay, SSR) or seen on an outpatient basis (hospitalization day, consultation)
• Affiliated patient or beneficiary of a social healthcare system
• Patient having given written consent

Exclusion Criteria:

• Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by court order or administration

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Blood sampling	Diagnostic test: Blood sampling; Blood sampling

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of patients diagnosed with iron deficiency on inclusion	The diagnosis of iron deficiency will be made from the measurements of the ferritinemia and CST: Ferritinemia < 100 µg/L and/or CST < 20%	Day 1

Collaborators and Investigators

• Sponsor: Vifor Pharma

Study record dates

Study Major Dates

• Study Start (Actual): November 15, 2022
• Primary Completion (Actual): December 9, 2022
• Study Completion (Actual): December 9, 2022

Study Registration Dates

• First Submitted: August 22, 2022
• First Submitted That Met QC Criteria: August 22, 2022
• First Posted (Actual): August 25, 2022

Study Record Updates

• Last Update Posted (Actual): March 28, 2025
• Last Update Submitted That Met QC Criteria: March 24, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Hematologic Diseases; Anemia; Iron Metabolism Disorders; Anemia, Hypochromic; Iron Deficiencies; Anemia, Iron-Deficiency
• Other Study ID Numbers: 2022-A00787-36

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No